Is Day One Biopharmaceuticals, Inc. (DAWN) a Buy, Sell, or Hold?
NASDAQ : DAWN
Day One Biopharmaceuticals, Inc.
$21.53 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 4.01M
- Market Capitalization
- $2.22B
- P/E Ratio
- -20.70
- Dividend Yield
- 0.00%
- Price Target
- $21.50
- Year High
- $21.53
- Year Low
- $5.64
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.02
Company Overview
NASDAQ
Jeremy Bender
Biotechnology
Healthcare
DAWN
181
US
USD
Liquidity Metrics
0.01
8.02
7.91
3.26
0.00
Sales & Valuation
$158.18M
14.06
5.05
-20.68
-1.04
Profitability
-$1.04
-$107.32M
-67.85%
-69.10%
-23.43%
-21.13%
P/E Metrics
-20.70
0.40
0.40
Analyst Price Target & Rating
$21.50
$21.50
$21.50
0/5
12 Analysts
0.14%
Financial Health Scores
18.80
3/9
$424.58M
$507.83M
$66.66M
-$109.3M
Key Metrics (TTM)
$2.03B
12.84
-19.24
8.02
-23.43%
-28.03%
-4.82%
-4.84%
117 days
Company Executives
| Name | Title |
|---|---|
| Lauren Merendino | Chief Commercial Officer |
| Jeremy Bender | Chief Executive Officer, President & Director |
| Heather Adkins Huet | Chief Scientific Officer |
| Joey Perrone | Senior Vice President of Finance & Investor Relations |
| John Stubenrauch | Chief Technology Officer |
| Jaa Roberson | Chief People Officer |
| Davy Chiodin | Chief Development Officer |
| Elly Barry | Chief Medical Officer |
| Michael J. Vasconcelles | Head of Research & Development |
| Adam Dubow | General Counsel |
| Charles N. York | Chief Operating Officer & Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California. ...
Frequently Asked Questions
-
What is the current Day One Biopharmaceuticals, Inc. (DAWN) stock price?
-
Day One Biopharmaceuticals, Inc.(NASDAQ:DAWN) stock price is $21.53 in the last trading session. During the trading session, DAWN stock reached the peak price of $21.53 while $5.635 was the lowest point it dropped to. The percentage change in DAWN stock occurred in the recent session was 0.0% while the dollar amount for the price change in DAWN stock was $0.
-
DAWN's industry and sector of operation?
-
The NASDAQ listed DAWN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DAWN?
-
Lauren Merendino | Chief Commercial Officer
Jeremy Bender | Chief Executive Officer, President & Director
Heather Adkins Huet | Chief Scientific Officer
Joey Perrone | Senior Vice President of Finance & Investor Relations
John Stubenrauch | Chief Technology Officer -
How many employees does DAWN have?
-
Number of DAWN employees currently stands at 181. DAWN operates from 395 Oyster Point Boulevard, Brisbane, CA 94080, US.
-
Link for DAWN official website?
-
Official Website of DAWN is: https://dayonebio.com
-
How do I contact DAWN?
-
DAWN could be contacted at phone #650 484 0899 and can also be accessed through its website. DAWN operates from 395 Oyster Point Boulevard, Brisbane, CA 94080, US.
-
How many shares of DAWN are traded daily?
-
The average number of DAWN shares traded daily for last 3 months was 4.01M.
-
What is the market cap of DAWN currently?
-
The market value of DAWN currently stands at $2.22B with its latest stock price at $21.53